EASL Journal Club
23 April 2024, 18:00 CET
Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab
EASL Quiz
The new Quiz is here!
Discover the case and test your Guidelines Knowledge
EASL Studio
Wednesday 1 May, 18:00 CET
Assessment of clinically significant portal hypertension in 2024 – Is it time to say goodbye to invasive measurements?
EASL Molecular Tumour Board
On demand!
Catch up with the presentation and discussion of this clinical case of cholangiocarcinoma.
EASL Policy Dialogues
Season 3 Episode 1 now available!
Rarity and parity – Addressing inequities in rare liver disease
Steatotic liver disease – the missing piece in the NCD puzzle
Now on-demand!
Discover the priorities and recommendations for the upcoming WHA77 agenda established by EASL, representatives from the WHO, patient advocate, NCD Alliance, and more !
You may also be interested in
Our Sponsors